Companies › Sardocor
2 active drug programs in 3 registered trials: 3 Phase 1; Cardiovascular; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SRD-001 AAV1-mediated SERCA2a gene therapy for SERCA2a enzyme replacement | ATP2A2 | Phase 1 | DMD-Associated Dilated Cardiomyopathy; Congestive Heart Failure | Oct 2027 |
| AAV1/SERCA2a Adeno-associated virus serotype 1 (AAV1) delivering SERCA2a gene to enhance cardiac calciu | ATP2A2 | Phase 1 | Heart Failure, Diastolic | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06224660 | SRD-001 | Phase 1 | DMD-Associated Dilated Cardiomyopathy | Cardiovascular | Oct 2027 |
| NCT04703842 | SRD-001 | Phase 1 | Congestive Heart Failure | Cardiovascular | Dec 2028 |
| NCT06061549 | AAV1/SERCA2a | Phase 1 | Heart Failure, Diastolic | Cardiovascular | Aug 2029 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.